Matches in SemOpenAlex for { <https://semopenalex.org/work/W100303634> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W100303634 endingPage "9" @default.
- W100303634 startingPage "333" @default.
- W100303634 abstract "The B-RAF kinase is among major targets of biological therapy of cancer. B-RAF acts in the MAP kinase pathway, being activated by any of the RAS G-proteins. Hyperactive B-RAF is typically detected in chemoresistant and radioresistant malignant metastatic melanoma. In this study, we focus on the reversible ATP-competitive inhibitor dabrafenib (GSK-2118436), which is now in phase III clinical trial for use in subjects with various cancers expressing hyperactive B-RAF. Dabrafenib is selective for B-RAFV600E and B-RAFV600K (less for B-RAFV600D) over wild-type B-RAF. Thus, similarly to vemurafenib (Zelboraf), suggested is mandatory pre-screening for activating B-RAF mutations in the cancer tissue of each subject. Dabrafenib inhibits neoplastic growth at concentrations 53.8 nM in plasma, which corresponds to 30 mg/kg qd p.o., or to --- 3 mg/kg qd i.v. Most of the cancers expressing hyperactive B-RAF respond to dabrafenib treatment, but the complete response is only rarely achieved. Toxic side effects include skin lesions, pyrexia, frequent fatigue, nausea and pain. Resistance to dabrafenib is frequently developed via de novo RAS mutations, leading to the disease relapse. The RAS G-protein is capable of signaling downstream not only through B-RAF, but also through closely related C-RAF, which circumvents the effects of the B-RAF inhibitor. Thus, dabrafenib should not be prescribed to subjects with neoplasias that are positive for activating RAS mutations. Since B-RAF mutations alone cause only the formation of benign naevi, since the tumors frequently and quickly acquire resistance to B-RAF inhibitors, and because the B-RAF-inhibitor-mediated treatment outcomes are severely affected by changes in the activity and expression of a number of signaling molecules (among them PI3K/mTOR, PTEN, AKT, MEK, PDGFRβ), it can be anticipated that dabrafenib treatment should be suggested only as a part of combined therapy targeting simultaneously the other pathways responsible for cancer onset and progression." @default.
- W100303634 created "2016-06-24" @default.
- W100303634 creator A5047225751 @default.
- W100303634 date "2012-01-01" @default.
- W100303634 modified "2023-09-25" @default.
- W100303634 title "[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase]." @default.
- W100303634 cites W1773110831 @default.
- W100303634 cites W1879616740 @default.
- W100303634 cites W1925900276 @default.
- W100303634 cites W2056883551 @default.
- W100303634 cites W2063324830 @default.
- W100303634 cites W2103845135 @default.
- W100303634 cites W2128542677 @default.
- W100303634 cites W2134471382 @default.
- W100303634 cites W2135925159 @default.
- W100303634 cites W2155305032 @default.
- W100303634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23102194" @default.
- W100303634 hasPublicationYear "2012" @default.
- W100303634 type Work @default.
- W100303634 sameAs 100303634 @default.
- W100303634 citedByCount "1" @default.
- W100303634 countsByYear W1003036342013 @default.
- W100303634 crossrefType "journal-article" @default.
- W100303634 hasAuthorship W100303634A5047225751 @default.
- W100303634 hasConcept C121608353 @default.
- W100303634 hasConcept C126322002 @default.
- W100303634 hasConcept C184235292 @default.
- W100303634 hasConcept C2776131300 @default.
- W100303634 hasConcept C2777658100 @default.
- W100303634 hasConcept C2778830669 @default.
- W100303634 hasConcept C2994587330 @default.
- W100303634 hasConcept C502942594 @default.
- W100303634 hasConcept C54355233 @default.
- W100303634 hasConcept C71924100 @default.
- W100303634 hasConcept C86803240 @default.
- W100303634 hasConceptScore W100303634C121608353 @default.
- W100303634 hasConceptScore W100303634C126322002 @default.
- W100303634 hasConceptScore W100303634C184235292 @default.
- W100303634 hasConceptScore W100303634C2776131300 @default.
- W100303634 hasConceptScore W100303634C2777658100 @default.
- W100303634 hasConceptScore W100303634C2778830669 @default.
- W100303634 hasConceptScore W100303634C2994587330 @default.
- W100303634 hasConceptScore W100303634C502942594 @default.
- W100303634 hasConceptScore W100303634C54355233 @default.
- W100303634 hasConceptScore W100303634C71924100 @default.
- W100303634 hasConceptScore W100303634C86803240 @default.
- W100303634 hasIssue "5" @default.
- W100303634 hasLocation W1003036341 @default.
- W100303634 hasOpenAccess W100303634 @default.
- W100303634 hasPrimaryLocation W1003036341 @default.
- W100303634 hasRelatedWork W150288523 @default.
- W100303634 hasRelatedWork W1560634350 @default.
- W100303634 hasRelatedWork W1980427440 @default.
- W100303634 hasRelatedWork W2029761866 @default.
- W100303634 hasRelatedWork W2142913791 @default.
- W100303634 hasRelatedWork W2265205727 @default.
- W100303634 hasRelatedWork W2563532854 @default.
- W100303634 hasRelatedWork W2790945713 @default.
- W100303634 hasRelatedWork W2808608845 @default.
- W100303634 hasRelatedWork W3023401146 @default.
- W100303634 hasVolume "25" @default.
- W100303634 isParatext "false" @default.
- W100303634 isRetracted "false" @default.
- W100303634 magId "100303634" @default.
- W100303634 workType "article" @default.